Cyclobenzaprine: Difference between revisions
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
==Administration== | ==Administration== | ||
*Type: | *Type: [[Muscle relaxant]] | ||
*Dosage Forms: | *Dosage Forms: | ||
*Routes of Administration: Oral | *Routes of Administration: Oral | ||
| Line 18: | Line 14: | ||
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: B | *[[Drug Ratings in Pregnancy|Pregnancy Rating]]: B | ||
*[[Lactation risk categories|Lactation risk]]: infant risk cannot be ruled out | *[[Lactation risk categories|Lactation risk]]: infant risk cannot be ruled out | ||
*'''[[High-risk geriatric medication]]!''' | |||
===Renal Dosing=== | ===Renal Dosing=== | ||
*Adult: | *Adult: | ||
*Pediatric: | *Pediatric: | ||
===Hepatic Dosing=== | ===Hepatic Dosing=== | ||
*Adult: Titrate slowly | *Adult: Titrate slowly | ||
| Line 29: | Line 28: | ||
*MAOI use, concomitantly or within 14 days | *MAOI use, concomitantly or within 14 days | ||
*Heart block or other serious arrhythmias, CHF | *Heart block or other serious arrhythmias, CHF | ||
==Adverse Reactions== | ==Adverse Reactions== | ||
===Serious=== | ===Serious=== | ||
| Line 37: | Line 37: | ||
*Bone marrow depression | *Bone marrow depression | ||
*Hepatitis | *Hepatitis | ||
===Common=== | ===Common=== | ||
*Somnolence, dizziness | *Somnolence, dizziness | ||
*Nausea, constipation | *Nausea, constipation | ||
==Pharmacology== | ==Pharmacology== | ||
*Half-life: ~18h for immediate release, 32h for extended release | *Half-life: ~18h for immediate release, 32h for extended release | ||
| Line 47: | Line 49: | ||
==Mechanism of Action== | ==Mechanism of Action== | ||
*Acts on CNS to reduce tonic somatic motor activity | *Acts on CNS to reduce tonic somatic motor activity | ||
==Toxicity== | |||
*Similar to [[Tricyclic antidepressant toxicity]], molecular structure similar and urine testing can be positive for TCAs | |||
*Can have anticholinergic toxidrome in overdose | |||
==Comments== | ==Comments== | ||
Latest revision as of 23:28, 20 May 2026
Administration
- Type: Muscle relaxant
- Dosage Forms:
- Routes of Administration: Oral
- Common Trade Names: Flexeril
Adult Dosing
- 5-10mg PO 1-3 times per day
Pediatric Dosing
- >15 y/o
- 5-10 mg TID
Special Populations
- Pregnancy Rating: B
- Lactation risk: infant risk cannot be ruled out
- High-risk geriatric medication!
Renal Dosing
- Adult:
- Pediatric:
Hepatic Dosing
- Adult: Titrate slowly
- Pediatric:
Contraindications
- Allergy to class/drug
- MAOI use, concomitantly or within 14 days
- Heart block or other serious arrhythmias, CHF
Adverse Reactions
Serious
- Neuroleptic malignant syndrome
- Serotonin syndrome
- Stroke
- Dysrhythmias, heart block
- Bone marrow depression
- Hepatitis
Common
- Somnolence, dizziness
- Nausea, constipation
Pharmacology
- Half-life: ~18h for immediate release, 32h for extended release
- Metabolism: hepatic
- Excretion: Urine
Mechanism of Action
- Acts on CNS to reduce tonic somatic motor activity
Toxicity
- Similar to Tricyclic antidepressant toxicity, molecular structure similar and urine testing can be positive for TCAs
- Can have anticholinergic toxidrome in overdose